Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab(Cleveland Clinic), Daniel C. Cho(NYU Langone Health), Mario Sznol(Yale University), Vassiliki A. Papadimitrakopoulou(Pfizer (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Ahsan Rizwan(Nektar Therapeutics (United States)), Salah-Eddine Bentebibel(The University of Texas MD Anderson Cancer Center), Brendan D. Curti(Providence Portland Medical Center), Ute Hoch(University of Arizona), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Ernesto Iacucci(Nektar Therapeutics (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Scott Gettinger(Yale Cancer Center), Mary Tagliaferri(Nektar Therapeutics (United States)), Michael E. Hurwitz(Yale University), Alison L. Hannah(CytomX Therapeutics (United States)), Christie Fanton(Nektar Therapeutics (United States)), Yijie Liao(Nektar Therapeutics (United States)), Patrick Hwu(Moffitt Cancer Center), Harriet M. Kluger(Yale Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 239
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k